一种新型BRCA1相关蛋白1异构体影响间皮瘤细胞对损害BRCA1介导DNA修复药物的反应
研究在恶性胸膜间皮瘤(MPM)细胞系与组织中鉴定出缺失部分催化结构域的新型BAP1剪接异构体BAP1Δ,其去泛素化活性低于全长BAP1;表达超过20% BAP1Δ的MPM细胞系对奥拉帕利细胞毒性更敏感,联用GDC0980后敏感性增强,GDC0980可诱导BRCA1下调。
要点
- 鉴定出缺失部分催化结构域的新型BAP1剪接异构体BAP1Δ,其去泛素化活性低于全长BAP1。
- BAP1Δ转录本在非肿瘤样本中比肿瘤样本更丰富。
- 表达超过20% BAP1Δ的MPM细胞系对奥拉帕利更敏感,联用GDC0980后敏感性增强。
核心结论
- 上述观察提示BAP1Δ确实调控DNA损伤反应并影响药物敏感性,作者认为或可研究高表达BAP1Δ的患者是否对PARP/PI3K-mTOR抑制剂有反应。
研究设计与样本
- 体外研究:用定量聚合酶链反应检测MPM与正常间皮细胞系及肿瘤与非肿瘤样本中BAP1异构体的表达。
- 用酸性提取核心组蛋白后Western blot分析组蛋白H2A泛素化水平,用免疫荧光检查BAP1异构体亚细胞定位。
- 用体外试验分析MPM细胞对PARP抑制剂及PI3K-mTOR双重抑制剂的存活反应。
主要发现
- 转染BAP1Δ的细胞去泛素化活性较全长BAP1降低。
- BAP1Δ转录本在非肿瘤样本中的表达比肿瘤样本更丰富。
- 表达超过20% BAP1Δ的MPM细胞系对奥拉帕利(PARP1抑制剂)细胞毒性更敏感。
- 奥拉帕利与GDC0980(PI3K-mTOR双重抑制剂)联用时该敏感性增强,GDC0980可诱导BRCA1下调。
临床怎么用
- 作者认为或可研究高表达BAP1Δ的患者是否对PARP/PI3K-mTOR抑制剂有反应;原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: BRCA1 associated protein1 (BAP1) is a tumor suppressor involved in multiple cellular processes such as transcriptional regulation, chromatin modification by deubiquitinating histone 2A, and DNA repair. BAP1 mutations are frequent in malignant pleural mesothelioma (MPM). Our aim was to functionally characterize a newly identified isoform of BAP1 and investigate the effects of its expression on drug sensitivity in MPM. METHODS: Expression of BAP1 isoforms was detected by quantitative polymerase chain reaction in MPM and normal mesothelium cell lines and tumor and nontumor samples. Histone H2A ubiquitination levels were analyzed by Western blot after acidic extraction of core histones. Subcellular localization of BAP1 isoforms was examined by immunofluorescence. MPM cell survival in response to poly(adenosine diphosphate-ribose) polymerase (PARP) and dual phosphoinositide 3-kinase (PI3K)-mammalian target of rapamycin (mTOR) inhibitors was analyzed by in vitro assays. RESULTS: We have identified a novel alternative splice isoform of BAP1 (BAP1Δ) that misses part of the catalytic domain. Cells transfected with BAP1Δ showed reduced deubiquitinating activity compared with full-length BAP1. The expression of BAP1Δ transcript is more abundant in nontumor than in tumor samples. MPM cell lines expressing more than 20% of BAP1Δ are more sensitive to olaparib (a PARP1 inhibitor) cytotoxicity, and this sensitivity is enhanced when olaparib treatment is combined with GDC0980 (a dual PI3K-mTOR inhibitor), which induces downregulation of BRCA1. CONCLUSIONS: These observations suggest that BAP1Δ does regulate DNA damage response and influences drug sensitivity. It might therefore be relevant to investigate whether patients with high expression of BAP1Δ may be responsive to PARP/PI3K-mTOR inhibitors.
引用
- Parrotta R, Okonska A, Ronner M, et al. A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair. J Thorac Oncol. 2017. PMID: 28389374. doi:10.1016/j.jtho.2017.03.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。